Aspergillosis Treatments
Find Aspergillosis Treatments
Brand Name
Noxafil
Generic Name
Posaconazole
View Brand Information FDA approval date: September 15, 2006
Classification: Azole Antifungal
Form: Injection, Tablet, Powder, Suspension, Solution
What is Noxafil (Posaconazole)?
Posaconazole delayed-release tablets is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Summary: Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) serves as a curative treatment modality for the vast majority of patients with hematological malignancies. Historically, due to the relatively high treatment-related mortality rate associated with Allo-HCT, this therapy was primarily administered to younger patients. However, the median age at onset of most hematological malignancies falls w...
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Summary: The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Summary: The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
Related Latest Advances
Brand Information
NOXAFIL (posaconazole)
1DOSAGE FORMS AND STRENGTHS
Noxafil injection
300 mg/16.7 mL (18 mg/mL) of posaconazole: Clear, colorless to yellow sterile liquid in a single-dose vial.
Noxafil Delayed-Release Tablets
100 mg of posaconazole: Yellow, coated, oblong tablets, debossed with "100" on one side.
Noxafil Oral Suspension
4,200 mg/105 mL (40 mg/mL) of posaconazole: White, cherry-flavored suspension in amber glass bottles with child-resistant closures.
Noxafil PowderMix for Delayed-Release Oral Suspension
300 mg: Off-white to yellowish powder for delayed-release oral suspension and a mixing liquid in a kit. The kit contains (1) Package A that contains single-use packets of Noxafil PowderMix, green notched tip syringes, blue notched tip syringes, mixing cups, mixing liquid bottle, and one bottle adapter for the mixing liquid bottle; and (2) Package B that contains green and blue notched tip syringes for additional supply
2ADVERSE REACTIONS
The following serious and otherwise important adverse reactions are discussed in detail in another section of the labeling:
- Arrhythmias and QT Prolongation
- Electrolyte Disturbances
- Pseudoaldosteronism
- Hepatic Toxicity
2.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of Noxafil cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
2.2Postmarketing Experience
The following adverse reaction has been identified during the post-approval use of Noxafil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
3DRUG INTERACTIONS
Table 15 and Table 17 include drugs with clinically important drug interactions when administered concomitantly with Noxafil and Noxafil PowderMix and instructions for preventing or managing them. Table 16 includes important drug interactions specific to the absorption of posaconazole administered as either Noxafil oral suspension or Noxafil PowderMix.
These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy
The following information was derived from data with Noxafil oral suspension or another posaconazole tablet formulation unless otherwise noted. All clinically important drug interactions with Noxafil oral suspension, except for those that affect the absorption of posaconazole (via gastric pH and motility), are considered relevant to clinically important drug interactions with Noxafil injection, Noxafil delayed-release tablets, and Noxafil PowderMix for delayed-release oral suspension
Consult the labeling of concomitantly used drugs to obtain further information about interactions with posaconazole.
3.1Effects of Noxafil and Noxafil PowderMix on Other Drugs
Posaconazole is a strong CYP3A4 inhibitor. Therefore, concomitant use of Noxafil may increase plasma concentrations of drugs that are CYP3A4 substrates
3.2Absence of Clinically Important Interaction with Noxafil and Noxafil PowderMix
Additional clinical studies demonstrated that no clinically important effects on zidovudine, lamivudine, indinavir, or caffeine were observed when administered with Noxafil 200 mg once daily; therefore, no dose adjustments are required for these drugs when coadministered with Noxafil 200 mg once daily.
No clinically relevant effects on the pharmacokinetics of Noxafil delayed-release tablets were observed during concomitant use with antacids, H
No clinically relevant effects on the pharmacokinetics of Noxafil oral suspension were observed during concomitant use with antacids, H
4OVERDOSAGE
There is no experience with overdosage of Noxafil injection and Noxafil delayed-release tablets.
During the clinical trials, some patients received Noxafil oral suspension up to 1,600 mg/day with no adverse reactions noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg twice daily Noxafil oral suspension for 3 days. No related adverse reactions were noted by the investigator.
Posaconazole is not removed by hemodialysis.
5DESCRIPTION
Noxafil and Noxafil PowderMix contain posaconazole, an azole antifungal agent.
Posaconazole is designated chemically as 4-[4-[4-[4-[[ (3
Posaconazole is a white powder with a low aqueous solubility.
Noxafil (posaconazole) Injection
Noxafil injection, for intravenous use, is a clear colorless to yellow, without preservatives sterile liquid essentially free of foreign matter. Each vial contains 300 mg of posaconazole and the following inactive ingredients: 6.68 g Betadex Sulfobutyl Ether Sodium (SBECD), 0.0033 g edetate disodium, hydrochloric acid and sodium hydroxide to adjust the pH to 2.6, and water for injection.
Noxafil (posaconazole) Delayed-Release Tablets
Noxafil delayed-release tablet, for oral use, is yellow, coated, and oblong and contains 100 mg of posaconazole. Each delayed-release tablet contains the following inactive ingredients: croscarmellose sodium, hydroxypropylcellulose, hypromellose acetate succinate, iron oxide yellow, Macrogol/PEG 3350, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol partially hydrolyzed, silicon dioxide, talc, and titanium dioxide.
Noxafil (posaconazole) Oral Suspension
Noxafil oral suspension is a white, cherry-flavored immediate-release suspension that contains 40 mg of posaconazole per mL and the following inactive ingredients: artificial cherry flavor, citric acid monohydrate, glycerin, liquid glucose, polysorbate 80, purified water, simethicone, sodium benzoate, sodium citrate dihydrate, titanium dioxide, and xanthan gum.
Noxafil PowderMix (posaconazole) for Delayed-Release Oral Suspension
Noxafil PowderMix for delayed-release oral suspension is supplied as a component of a kit. Each kit contains Noxafil as an off-white to yellowish powder for delayed-release oral suspension, a bottle of mixing liquid, two 3 mL (green) notched tip syringes, two 10 mL (blue) notched tip syringes, two mixing cups, and one bottle adapter for the mixing liquid bottle.
- Noxafil PowderMix for delayed-release oral suspension contains 300 mg of posaconazole and the following inactive ingredient: hypromellose acetate succinate.
- The mixing liquid contains: anhydrous citric acid, antifoam Af emulsion, berry citrus sweet flavor, carboxymethylcellulose sodium, carrageenan calcium sulfate trisodium phosphate, glycerin, methylparaben, microcrystalline cellulose, potassium sorbate, propylparaben, purified water, sodium citrate, sodium phosphate monobasic monohydrate, sodium saccharin, sorbitol solution, and xanthan gum.
6PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (
Important Administration Instructions
Noxafil Delayed-Release Tablets
Advise patients that Noxafil delayed-release tablets must be swallowed whole and not divided, crushed, or chewed.
Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not remember until it is within 12 hours of the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.
Noxafil Oral Suspension
Advise patients to take each dose of Noxafil oral suspension during or immediately (i.e., within 20 minutes) following a full meal. In patients who cannot eat a full meal, each dose of Noxafil oral suspension should be administered with a liquid nutritional supplement or an acidic carbonated beverage (e.g., ginger ale) in order to enhance absorption.
Instruct patients that if they miss a dose, they should take it as soon as they remember. However, if it is almost time for the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.
Noxafil PowderMix for Delayed-Release Oral Suspension
Instruct parents and/or caregivers that ONLY the provided notched tip syringes can be used to administer Noxafil PowderMix for delayed-release oral suspension to pediatric patients.
Advise patients to take Noxafil PowderMix for delayed-release oral suspension with food.
Drug Interactions
Advise patients to inform their physician immediately if they:
- develop severe diarrhea or vomiting.
- are currently taking drugs that are known to prolong the QTc interval and are metabolized through CYP3A4.
- are currently taking a cyclosporine or tacrolimus, or they notice swelling in an arm or leg or shortness of breath.
- are taking other drugs or before they begin taking other drugs as certain drugs can decrease or increase the plasma concentrations of posaconazole.
Serious and Potentially Serious Adverse Reactions
Advise patients to inform their physician immediately if they:
- notice a change in heart rate or heart rhythm or have a heart condition or circulatory disease. Noxafil can be administered with caution to patients with potentially proarrhythmic conditions.
- are pregnant, plan to become pregnant, or are nursing.
- have liver disease or develop itching, nausea or vomiting, their eyes or skin turn yellow, they feel more tired than usual or feel like they have the flu.
- have ever had an allergic reaction to other antifungal medicines such as ketoconazole, fluconazole, itraconazole, or voriconazole.
Hereditary Fructose Intolerance (HFI)
Inform patients and caregivers that Noxafil PowderMix for delayed-release oral suspension contains sorbitol and can be life-threatening when administered to patients with hereditary fructose intolerance (HFI)
7PRINCIPAL DISPLAY PANEL - 105 mL Bottle Carton
NDC 0085-1328-01
NOXAFIL
(posaconazole)
(posaconazole)
Oral Suspension
200 mg/5 mL
Each mL contains: 40 mg posaconazole.
Attention: Noxafil Oral Suspension is
SHAKE WELL BEFORE EACH USE.
Take with a meal, or a nutritional supplement,
Carton contains measured dosing spoon.
Rx only
8PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle Label
NDC 0085-4324-02
Noxafil
100 mg
Each tablet contains 100 mg posaconazole.
Attention: Noxafil Oral Suspension and Delayed-
Rx only
60 Tablets
9PRINCIPAL DISPLAY PANEL - 16.7 mL Vial Carton
NDC 0085-4331-01
Noxafil
300 mg/16.7 mL
For Intravenous Use Only
Requires further dilution prior to infusion.
Rx only
Sterile Single-Dose Vial
Discard Unused Portion
Sterile Single-Dose Vial
Discard Unused Portion
10PRINCIPAL DISPLAY PANEL - 300 mg Carton
NDC 0085-2224-02
Noxafil
300 mg
For Pediatric Use
Each packet contains 300 mg posaconazole.
Attention: Noxafil PowderMix for Delayed-Release Oral Suspension is NOT
substitutable with Noxafil Oral Suspension due to differences in the
dosing of each formulation.
substitutable with Noxafil Oral Suspension due to differences in the
dosing of each formulation.
Use only the notched-tip syringes and mixing liquid provided with this kit.
Rx only
8 packets
8 packets
Multi-Dose Kit A
Additional notched-tip syringes are provided in
Package B with this kit.
DIRECTIONS FOR USE:
See instructions for use booklet and prescribing
information for additional information.
Additional notched-tip syringes are provided in
Package B with this kit.
DIRECTIONS FOR USE:
See instructions for use booklet and prescribing
information for additional information.
